MedXY
Not signed in Sign in / Register
Skip to content
medxy logo Medxy AI
  • Specialties
    • Allergy & Immunology
    • Anesthesiology
    • Cardiology
    • Critical Care
    • Dermatology
    • Diabetes & Endocrinology
    • Emergency Medicine
    • Family Medicine & Nutrition
    • Gastroenterology
    • General Surgery
    • Hematology-Oncology
    • HIV/AIDS
    • Infectious Diseases
    • Internal Medicine
    • Nephrology
    • Neurology
    • Nursing & care
    • OB/GYN & Women’s Health
    • Oncology
    • Ophthalmology
    • Orthopedics
    • Otorhinolaryngology
    • Pathology & Lab Medicine
    • Pediatrics
    • Plastic Surgery
    • Psychiatry
    • Public Health
    • Radiology
    • Respiratory
    • Rheumatology
    • Urology
  • Clinical Updates
  • Medical News
  • iDoctor
  • Specialties
    • Allergy & Immunology
    • Anesthesiology
    • Cardiology
    • Critical Care
    • Dermatology
    • Diabetes & Endocrinology
    • Emergency Medicine
    • Family Medicine & Nutrition
    • Gastroenterology
    • General Surgery
    • Hematology-Oncology
    • HIV/AIDS
    • Infectious Diseases
    • Internal Medicine
    • Nephrology
    • Neurology
    • Nursing & care
    • OB/GYN & Women’s Health
    • Oncology
    • Ophthalmology
    • Orthopedics
    • Otorhinolaryngology
    • Pathology & Lab Medicine
    • Pediatrics
    • Plastic Surgery
    • Psychiatry
    • Public Health
    • Radiology
    • Respiratory
    • Rheumatology
    • Urology
  • Clinical Updates
  • Medical News
  • iDoctor
  • facebook.com
  • twitter.com
  • t.me
  • instagram.com
  • youtube.com
Subscribe

Chăm sóc dựa trên giá trị

  • Home
  • Chăm sóc dựa trên giá trị
Medicare’s Oncology Care Model Did Not Increase Systemic Therapy Starts and Was Linked to Lower Use in Poor-Prognosis Cancer
Posted innews Oncology Public Health

Medicare’s Oncology Care Model Did Not Increase Systemic Therapy Starts and Was Linked to Lower Use in Poor-Prognosis Cancer

Posted by By MedXY 05/05/2026
A matched difference-in-differences study found that the Oncology Care Model did not increase systemic therapy initiation overall and was associated with lower treatment initiation and lower spending in poor-prognosis cancers.
Read More
The Limits of Risk-Based Contracting: Dissecting Healthcare Utilization and Low-Value Service Trends in Medicare Advantage
Posted inMedical News news Public Health

The Limits of Risk-Based Contracting: Dissecting Healthcare Utilization and Low-Value Service Trends in Medicare Advantage

Posted by By MedXY 01/06/2026
This evidence-based review examines whether the transition to risk-based contracts in Medicare Advantage successfully reduces healthcare utilization and low-value care, highlighting the discrepancy between financial incentives and clinical practice changes.
Read More
  • Intravitreal Bevacizumab versus Laser Therapy in Retinopathy of Prematurity: Analyzing Retreatment Rates, Timing, and Risk Predictors
  • Unraveling the Complex 3D Architecture of Outer Retinal Tubulation in Bietti Crystalline Dystrophy
  • Idiopathic Subglottic Stenosis in Pregnancy: Safety, Clinical Course, and Management Insights from a Case-Control Study
  • Rare But Risky: Clinical Implications of Pneumothorax Following Thyroidectomy and Parathyroidectomy
  • Navigating the Shift: Insights into a Department’s Transition from Total to Intracapsular Tonsillectomy
  • About us
  • Contact us
  • MedXY story
  • Privacy Policy
  • Subscribe Now!
  • 账号

  • English
  • 日本語
  • Tiếng Việt
  • 中文

Alzheimer's disease artificial intelligence atrial fibrillation biomarkers breast cancer Cardiology cardiovascular disease cardiovascular risk chronic kidney disease clinical trial clinical trials critical care diabetes epidemiology GLP-1 receptor agonists heart failure hepatocellular carcinoma Hypertension immunotherapy inflammation MASLD mental health Mortality multiple myeloma myocardial infarction nutrition obesity older adults oncology Pediatrics precision medicine Pregnancy prognosis public health quality of life randomized clinical trial randomized controlled trial risk stratification semaglutide SGLT2 inhibitors stroke targeted therapy type 1 diabetes type 2 diabetes women's health

Your health, we care

Copyright 2026 — Medxy AI. All rights reserved.
Scroll to Top